Kenneth S Zuckerman
Overview
Explore the profile of Kenneth S Zuckerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kesselheim J, Clayton C, Fritz J, Smith R, Gitlin S, Reid E, et al.
J Cancer Educ
. 2018 Apr;
34(4):719-724.
PMID: 29682694
Clinician educators at academic medical centers often lack the community, mentorship, and faculty development to support their missions around education scholarship and teaching. Inadequate support for clinician educators can lead...
2.
Kuykendall A, Shah S, Talati C, Al Ali N, Sweet K, Padron E, et al.
Ann Hematol
. 2017 Dec;
97(3):435-441.
PMID: 29189896
Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF). Unfortunately, many patients must discontinue ruxolitinib, at which time treatment options are not...
3.
Kuykendall A, Talati C, Al Ali N, Sweet K, Padron E, Sallman D, et al.
Clin Lymphoma Myeloma Leuk
. 2017 Sep;
17(12):e45-e53.
PMID: 28869184
Introduction/background: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm that presents with a heterogeneous clinical phenotype and prognosis. Before the US Food and Drug Administration approval of ruxolitinib, treatment options were...
4.
Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, et al.
Blood
. 2017 Feb;
129(13):1881-1883.
PMID: 28159734
No abstract available.
5.
Suleiman Y, Dalia S, Liu J, Bowers J, Padron E, Lancet J, et al.
Leuk Res
. 2016 Feb;
42:52-8.
PMID: 26894965
Transformation of essential thrombocythemia (ET) to myelodysplastic syndromes or acute myeloid leukemia is infrequent, comprising 1-5% of cases with dismal clinical outcome. Studies on prognosis in ET patients with leukemic...
6.
Kiss R, Polgar T, Kirabo A, Sayyah J, Figueroa N, List A, et al.
Bioorg Med Chem Lett
. 2009 May;
19(13):3598-601.
PMID: 19447617
Janus kinase 2 (JAK2) plays a crucial role in the pathomechanism of myeloproliferative disorders and hematologic malignancies. A somatic mutation of JAK2 (Val617Phe) was previously shown to occur in 98%...
7.
Wolvetang E, Pera M, Zuckerman K
Biochem Biophys Res Commun
. 2007 Sep;
363(3):610-5.
PMID: 17900528
Gap junction intracellular communication (GJIC) allows the direct transport of small molecules between adjacent cells. We hypothesized that siRNAs in one hESC could inhibit target RNA expression in another hESC...
8.
Hu X, Cui D, Moscinski L, Zhang X, Maccachero V, Zuckerman K
Cytokine
. 2007 Apr;
37(2):155-62.
PMID: 17459720
Transforming Growth Factor-beta (TGFbeta) is known to be a negative regulator of G1 cyclin/cdk activity. It is not clear whether TGFbeta has any effect on G2 checkpoint kinases. We have...
9.
Crist T, Barr W, Linas S, Zuckerman K
Am J Med
. 2004 Feb;
116(5):359-62.
PMID: 14984829
No abstract available.
10.
Hu X, Bryington M, Fisher A, Liang X, Zhang X, Cui D, et al.
J Biol Chem
. 2002 Feb;
277(19):16528-37.
PMID: 11864973
Tumor necrosis factor-alpha (TNF) is well known for its cytotoxic effect on malignant cells. Its role in cell cycle control is relatively less known. In this study, we found that...